What causes mdr tb

Overview

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis infection that is resistant to at least two of the most powerful anti-TB drugs: isoniazid and rifampicin. These drugs are considered the cornerstones of standard TB treatment. The emergence and spread of MDR-TB pose a significant global health challenge, complicating treatment efforts and leading to poorer health outcomes for affected individuals.

Understanding the causes of MDR-TB is crucial for effective prevention and control strategies. It's important to differentiate between the initial infection with TB bacteria and the development of drug resistance. While TB is caused by the bacterium Mycobacterium tuberculosis, MDR-TB arises when these bacteria evolve to survive exposure to specific anti-TB medications.

What Causes MDR-TB?

Incomplete or Improper Treatment

The most common and direct cause of MDR-TB is the failure to adhere to the prescribed treatment regimen for drug-susceptible TB. Standard TB treatment involves a combination of several drugs taken for an extended period, typically 6 to 9 months. If a patient:

• Does not take their medications regularly or stops taking them too early, the bacteria that survive the initial drug exposure can develop resistance.
• Misses doses, the concentration of the drug in the body may drop below the level needed to kill all the bacteria, allowing the stronger, more resistant ones to multiply.
• Does not complete the full course of treatment, even if they feel better, some persistent bacteria might remain and develop resistance.

This is why completing the entire course of prescribed medication, exactly as directed by a healthcare provider, is paramount for successful TB treatment and preventing the development of drug resistance.

Poor Quality Drugs or Incorrect Drug Regimens

The quality of anti-TB drugs is another critical factor. If the drugs used are of poor quality, contain insufficient amounts of the active ingredient, or are counterfeit, they may not be potent enough to kill the bacteria effectively. This sub-lethal exposure can also contribute to the development of drug resistance.

Similarly, using incorrect drug regimens—for instance, using too few drugs, using drugs at the wrong dose, or using drugs that are not effective against the specific strain of TB—can also lead to treatment failure and the emergence of MDR-TB.

Transmission of Drug-Resistant Strains

MDR-TB can also be acquired through transmission. If a person is infected with a strain of Mycobacterium tuberculosis that is already resistant to drugs, they will develop MDR-TB from the outset. This can happen through:

• Direct transmission of MDR-TB bacteria from an infected person to another, usually through airborne droplets released when an infected person coughs, sneezes, or speaks.
• In some cases, prior inadequate treatment can lead to the development of drug-resistant bacteria within a person, which can then be transmitted to others.

Other Contributing Factors

• Patient Adherence: Social, economic, and logistical factors can make it difficult for patients to adhere to treatment. These include poverty, lack of access to healthcare facilities, side effects of medications, lack of social support, and stigma associated with TB.
• Healthcare System Weaknesses: Weaknesses in TB control programs, such as inconsistent drug supply, inadequate laboratory capacity for drug susceptibility testing, and insufficient training for healthcare workers, can contribute to the problem.
• Human Immunodeficiency Virus (HIV) Co-infection: People living with HIV are more vulnerable to developing TB and may have a higher risk of developing drug-resistant TB if their HIV infection is not well-managed, or if their TB treatment is compromised.
• Improper Use of Drugs: The misuse of antibiotics in general, not just for TB, can contribute to the overall pool of drug-resistant bacteria in the community.

Addressing MDR-TB requires a multifaceted approach, focusing on strengthening TB treatment programs, ensuring access to quality drugs, improving diagnostics, and supporting patients to complete their treatment. Public awareness and education are also vital to combat stigma and encourage timely diagnosis and treatment.